VI-1121 for the Treatment Alzheimer's Disease

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease

The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.

Inclusion Criteria:

• clinical diagnosis of Alzheimer's disease
• CT or MRI within 2 years prior to study
• stable dose of current Alzheimer's treatment for at least 3 months

Exclusion Criteria:

• advanced, severe, progressive or unstable disease
• history of cerebrovascular disease or myocardial infarction within 6 months